Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays.

[1]  N. Copeland,et al.  Transposon mutagenesis identifies genes and cellular processes driving epithelial-mesenchymal transition in hepatocellular carcinoma , 2016, Proceedings of the National Academy of Sciences.

[2]  James H. Liu,et al.  Proteoglycans in Leiomyoma and Normal Myometrium , 2016, Reproductive Sciences.

[3]  M. Carneiro.  Stem cells and uterine leiomyomas: What is the evidence? , 2016, JBRA assisted reproduction.

[4]  M. Abbasi,et al.  The study of MED12 gene mutations in uterine leiomyomas from Iranian patients , 2016, Tumor Biology.

[5]  L. Aaltonen,et al.  Integrated data analysis reveals uterine leiomyoma subtypes with distinct driver pathways and biomarkers , 2016, Proceedings of the National Academy of Sciences.

[6]  U. Surti,et al.  High‐resolution microarray analysis unravels complex Xq28 aberrations in patients and carriers affected by X‐linked blue cone monochromacy , 2016, Clinical genetics.

[7]  T. Järvinen,et al.  Decorin: A Growth Factor Antagonist for Tumor Growth Inhibition , 2015, BioMed research international.

[8]  R. Tjian,et al.  A specific E3 ligase/deubiquitinase pair modulates TBP protein levels during muscle differentiation , 2015, eLife.

[9]  U. Surti,et al.  Med12 gain-of-function mutation causes leiomyomas and genomic instability. , 2015, The Journal of clinical investigation.

[10]  C. Simón,et al.  Overexpression of the truncated form of High Mobility Group A proteins (HMGA2) in human myometrial cells induces leiomyoma-like tissue formation. , 2015, Molecular human reproduction.

[11]  Jun Ye,et al.  High-resolution melting analysis of MED12 mutations in uterine leiomyomas in Chinese patients. , 2015, Genetic testing and molecular biomarkers.

[12]  R. Booton,et al.  HUWE1 Ubiquitylates and Degrades the RAC Activator TIAM1 Promoting Cell-Cell Adhesion Disassembly, Migration, and Invasion , 2014, Cell reports.

[13]  Shiow-Ju Lee,et al.  Targeting a ribonucleoprotein complex containing the caprin-1 protein and the c-Myc mRNA suppresses tumor growth in mice: an identification of a novel oncotarget , 2014, Oncotarget.

[14]  S. Bulun,et al.  Tissue-Specific Stem Cells in the Myometrium and Tumor-Initiating Cells in Leiomyoma1 , 2014, Biology of reproduction.

[15]  Min Ju Park,et al.  Mutations in Exon 1 Highlight the Role of MED12 in Uterine Leiomyomas , 2014, Human mutation.

[16]  C. Tomomori-Sato,et al.  Subunit Architecture and Functional Modular Rearrangements of the Transcriptional Mediator Complex , 2014, Cell.

[17]  J. Bullerdiek,et al.  Cell cultures in uterine leiomyomas: Rapid disappearance of cells carrying MED12 mutations , 2014, Genes, chromosomes & cancer.

[18]  L. Aaltonen,et al.  Exomic landscape of MED12 mutation‐negative and ‐positive uterine leiomyomas , 2014, International journal of cancer.

[19]  Jian-jun Wei,et al.  MED12 and HMGA2 mutations: Two independent genetic events in uterine leiomyoma and leiomyosarcoma , 2014, Modern Pathology.

[20]  Jia Chen,et al.  Caprin-1 is a novel microRNA-223 target for regulating the proliferation and invasion of human breast cancer cells. , 2013, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[21]  Anne-Marie Cleton-Jansen,et al.  Mediator complex subunit 12 exon 2 mutation analysis in different subtypes of smooth muscle tumors confirms genetic heterogeneity. , 2013, Human pathology.

[22]  B. Fuchs,et al.  Caprin-1, a novel Cyr61-interacting protein, promotes osteosarcoma tumor growth and lung metastasis in mice. , 2013, Biochimica et biophysica acta.

[23]  L. Aaltonen,et al.  Characterization of uterine leiomyomas by whole-genome sequencing. , 2013, The New England journal of medicine.

[24]  Ricardo Henao,et al.  A Network of Substrates of the E3 Ubiquitin Ligases MDM2 and HUWE1 Control Apoptosis Independently of p53 , 2013, Science Signaling.

[25]  J. Fletcher,et al.  MED12 mutations in leiomyosarcoma and extrauterine leiomyoma , 2013, Modern Pathology.

[26]  R. Shiekhattar,et al.  Activating RNAs associate with Mediator to enhance chromatin architecture and transcription , 2013, Nature.

[27]  A. Mehdizadeh,et al.  Role of endocrine disrupting chemicals in the occurrence of benign uterine leiomyomata: special emphasis on AhR tissue levels. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[28]  L. Aaltonen,et al.  Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer , 2012, British Journal of Cancer.

[29]  F. Chibon,et al.  MED12 Alterations in Both Human Benign and Malignant Uterine Soft Tissue Tumors , 2012, PloS one.

[30]  Murat Sincan,et al.  Detecting false‐positive signals in exome sequencing , 2012, Human mutation.

[31]  J. Mullikin,et al.  Analysis of DNA sequence variants detected by high‐throughput sequencing , 2012, Human mutation.

[32]  U. Surti,et al.  Whole Exome Sequencing in a Random Sample of North American Women with Leiomyomas Identifies MED12 Mutations in Majority of Uterine Leiomyomas , 2012, PloS one.

[33]  L. Aaltonen,et al.  MED12 exon 2 mutations are common in uterine leiomyomas from South African patients , 2011, Oncotarget.

[34]  L. Aaltonen,et al.  MED12, the Mediator Complex Subunit 12 Gene, Is Mutated at High Frequency in Uterine Leiomyomas , 2011, Science.

[35]  A. Iavarone,et al.  The HECT-domain ubiquitin ligase Huwe1 controls neural differentiation and proliferation by destabilizing the N-Myc oncoprotein , 2008, Nature Cell Biology.

[36]  Jonathan R. Hall,et al.  Cdc6 stability is regulated by the Huwe1 ubiquitin ligase after DNA damage. , 2007, Molecular biology of the cell.

[37]  P. Nederlof,et al.  A multiplex PCR predictor for aCGH success of FFPE samples , 2005, British Journal of Cancer.

[38]  K. Helin,et al.  The Ubiquitin Ligase HectH9 Regulates Transcriptional Activation by Myc and Is Essential for Tumor Cell Proliferation , 2005, Cell.

[39]  Jun Qin,et al.  ARF-BP1/Mule Is a Critical Mediator of the ARF Tumor Suppressor , 2005, Cell.

[40]  R. M. Cesar,et al.  A comparative analysis of structure and spatial distribution of decorin in human leiomyoma and normal myometrium. , 2003, Biochimica et biophysica acta.

[41]  C. Morton,et al.  The del(7q) subgroup in uterine leiomyomata: genetic and biologic characteristics. Further evidence for the secondary nature of cytogenetic abnormalities in the pathobiology of uterine leiomyomata. , 1997, Cancer genetics and cytogenetics.

[42]  T Skorski,et al.  De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[43]  U. Surti,et al.  Subgroups of uterine leiomyomas based on cytogenetic analysis. , 1991, Human pathology.

[44]  A. Patel,et al.  The frequency of uterine leiomyomas. , 1990, American journal of clinical pathology.

[45]  U. Surti,et al.  Supplemental Material for : Med 12 Gain-of-Function Mutation Causes Leiomyomas and Genomic Instability , 2015 .

[46]  Y. Shimono,et al.  Afadin/AF-6 and canoe: roles in cell adhesion and beyond. , 2013, Progress in molecular biology and translational science.

[47]  David B Dunson,et al.  High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. , 2003, American journal of obstetrics and gynecology.

[48]  O. Khorram,et al.  Uterine and ovarian aryl hydrocarbon receptor (AHR) and aryl hydrocarbon receptor nuclear translocator (ARNT) mRNA expression in benign and malignant gynaecological conditions. , 2002, Molecular human reproduction.

[49]  C. Morton,et al.  Genetics of uterine leiomyomata. , 2000, Genes, chromosomes & cancer.